Discontinuation report MOVAPO
| Report ID | 207624 |
| Drug Identification Number | 02459132 |
| Brand name | MOVAPO |
| Common or Proper name | APOMORPHINE HYDROCHLORIDE |
| Company Name | PALADIN PHARMA INC. |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | APOMORPHINE HYDROCHLORIDE |
| Strength(s) | 10MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | 5x 3mL |
| ATC code | N04BC |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2023-10-31 |
| Actual discontinuation date | |
| Remaining supply date | 2023-10-01 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | Yes |
| Contact Address | 100 BLVD ALEXIS-NIHON, SUITE 600 MONTREAL, QUEBEC CANADA H4M 2P2 |
| Company contact information | 1-866-340-1112 paladincs@endo.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2023-11-17 | English | Compare |
| v2 | 2023-10-20 | French | Compare |
| v1 | 2023-10-20 | English | Compare |
Showing 1 to 3 of 3